Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Identification and Characterization of USP19 Inhibitors to Prevent Muscle Atrophy

FY 2020-21

Summary
Currently, there are no approved therapies for muscleatrophy, a complication of many common chronic disorders such as cancer, heartdisease and lung disease. In muscle atrophy, muscles weaken over time, whichreduces the patient's quality of life and survival. The ubiquitin-proteasomesystem has been shown to mediate the loss of muscle mass. Specifically, adeubiquitinating enzyme, ubiquitin-specific protease 19 (USP19) has been shownby our laboratory and others to be involved in muscle atrophy. When micemissing the USP19 gene are subjected to treatments that cause muscle atrophy,they lose less muscle mass compared to similarly treated normal mice. Thissuggests that a drug that inhibits USP19 may mimic the effect of loss of USP19and be an effective way to prevent muscle atrophy in these chronic diseases.Therefore, we propose to use a new method based on bioluminescence resonanceenergy transfer (BRET), that bypasses a hurdle to drug discovery in theubiquitin-proteasome system to screen a library of 110,000 small molecule compoundsfor ones that can potentially inhibit USP19. We will then test them further to identify theeffective and specific compounds. Such effective inhibitors could be developedfurther into drugs to improve the quality of life and survival of patients.Success in these proposed studies would also confirm the utility of our newmethod and expand its use to identify drugs.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449522
Name
Huynh Julie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification and Characterization of USP19 Inhibitors to Prevent Muscle Atrophy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Deubiquitinating Enzymes; Diabetes; Muscle Atrophy; Small Molecule Inhibitors; Ubiquitin
Abstract
Currently, there are no approved therapies for muscleatrophy, a complication of many common chronic disorders such as cancer, heartdisease and lung disease. In muscle atrophy, muscles weaken over time, whichreduces the patient's quality of life and survival. The ubiquitin-proteasomesystem has been shown to mediate the loss of muscle mass. Specifically, adeubiquitinating enzyme, ubiquitin-specific protease 19 (USP19) has been shownby our laboratory and others to be involved in muscle atrophy. When micemissing the USP19 gene are subjected to treatments that cause muscle atrophy,they lose less muscle mass compared to similarly treated normal mice. Thissuggests that a drug that inhibits USP19 may mimic the effect of loss of USP19and be an effective way to prevent muscle atrophy in these chronic diseases.Therefore, we propose to use a new method based on bioluminescence resonanceenergy transfer (BRET), that bypasses a hurdle to drug discovery in theubiquitin-proteasome system to screen a library of 110,000 small molecule compoundsfor ones that can potentially inhibit USP19. We will then test them further to identify theeffective and specific compounds. Such effective inhibitors could be developedfurther into drugs to improve the quality of life and survival of patients.Success in these proposed studies would also confirm the utility of our newmethod and expand its use to identify drugs.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Huynh, Julie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~